摘要
目的:观察COX-2特异性抑制剂塞来昔布,联合多西紫杉醇+顺铂(TP)方案用于蒽环类药物治疗失败的乳腺癌转移瘤的疗效及毒性反应。方法:35例乳腺癌转移瘤采用TP方案治疗:多西紫杉醇75mg/m2,d1,顺铂30mg/m2,d1-d3,静脉注射;塞来昔布400mg,口服,2次/日,d1-d21。3周为1个周期,2个周期化疗后评价疗效及毒性反应。结果:35例患者共接受122周期化疗,中位化疗周期4个(2-6个周期),总有效率(overall remission rate,RR)为65.71%(23/35),其中临床完全缓解(clinical complete remission,cCR)6例,部分缓解(partial remission,PR)17例,稳定(stable disease,SD)11例,进展(progressive disease,PD)1例。全组随访6-30个月,中位疾病进展时间(time to progress,TTP)为8.5个月;中位生存时间18个月。结论:塞来昔布联合TP方案治疗蒽环类耐药乳腺癌转移瘤效果良好,毒性反应可以耐受。
Objective： To evaluate the clinical effect and toxicity of cyclooxygenase -2 selective inhibitor, celecoxib, combined with docetaxel and cisplatin for anthracycline - resistant metastasitic breast cancer. Methods： Thirty five patients with anthracycline - resistant metastasitic breast cancer were treated with regimen： docetaxel wasgiven at a dose of 75 g/m^2 on day 1 , cisplatin 30mg/m^2 on day 1 - 3, celecoxib was given at a dose of 400mg, twice daily, for dl -21,3 weeks was one circle, after at least 2 circles, the clinical effect and toxicity were evaluated. Re- salts： Thirty five patients received 122 circles, overall remission rate （RR） was 65.71% （23/35）, clinical complete remission（cCR） 6 cases, partial remission （PR） 17cases, stable disease （SD） 11 cases, progressive disease （PD） 1 case. Followed for 6 -30 months,the median time to progress （TTP）was 8.5months, the median survival time was 18 months. Condusion： Combination of cyclooxygenase -2 selective inhibitor, celecoxib, with doeetaxel and cisplatin regimen is an effective method to treat anthracycline - resistant metastasitic breast cancer with tolerable toxicity.
出处
《现代肿瘤医学》
CAS
2008年第4期582-585,共4页
Journal of Modern Oncology
